Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2025
Reporting Period: Event-based report for November 13, 2025.
Business Context: The Company is an emerging growth company incorporated in Texas, with principal executive offices in Dallas. The filing primarily addresses a strategic partnership announcement.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
Strategic Partnership Announcement: On November 13, 2025, Mangoceuticals, Inc. announced a partnership with Eli Lilly and Novo Nordisk. The stated objective of this partnership is to deliver affordable access to the medications Zepbound and Wegovy. Details regarding the financial terms or operational scope of this partnership are contained in the press release filed as Exhibit 99.1, which is incorporated by reference.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing contains forward-looking statements regarding the partnership and future expectations. These statements are identified by terms such as "estimate," "expects," "project," and "believe."
Risks and Uncertainties: The Company explicitly states that actual results may differ materially from these expectations due to known and unknown risks, uncertainties, and factors outside the Company's control. The Company undertakes no obligation to update these statements.
Outlook: No specific financial guidance or quantitative outlook is provided in this filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2025) for specific terms, scope, and financial implications of the partnership with Eli Lilly and Novo Nordisk.
- Verify the operational status of the partnership and any regulatory approvals required for the distribution of Zepbound and Wegovy.
- Consult recent Form 10-Q or Form 10-K filings for the Company's current financial condition, as this 8-K does not include financial data.
- Assess the Company's history of emerging growth company status and any associated reporting exemptions.